top of page

Executive Team

Under the leadership of of Interim Chief Executive Officer, Mr. Thane Wettig FibroGen’s executive team includes accomplished leaders with deep and broad experience. Supported by a staff of approximately 475 employees worldwide, we are focused on delivering first-in-class medicines for the treatment of unmet medical needs.

Thane Wettig

Interim Chief Executive Officer

Kirk Christoffersen

Chief Business Officer

Christine L. Chung

Senior Vice President,
China Operations

Juan Graham

Chief Financial Officer

John Hunter, Ph.D.

Chief Scientific Officer

Rahul Rajan Kaushik, Ph.D.

Senior Vice President of Pharmaceutical Development, Technical Operations and Manufacturing

Michael D. Lowenstein,

Chief Legal Officer

Tricia Stewart

Chief People Officer

Our Leadership

We are putting substantial expertise to work in
developing and commercializing novel therapeutics.

bottom of page